These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 8796975

  • 1. Disease-modifying antirheumatic drugs, including methotrexate, gold, sulfasalazine, antimalarials, and D-penicillamine.
    Conaghan PG, Brooks P.
    Curr Opin Rheumatol; 1996 May; 8(3):176-82. PubMed ID: 8796975
    [Abstract] [Full Text] [Related]

  • 2. Disease-modifying antirheumatic drugs.
    Conaghan PG, Lehmann T, Brooks P.
    Curr Opin Rheumatol; 1997 May; 9(3):183-90. PubMed ID: 9204252
    [Abstract] [Full Text] [Related]

  • 3. Disease-modifying antirheumatic drugs, including methotrexate, gold, antimalarials, and D-penicillamine.
    Conaghan PG, Brooks P.
    Curr Opin Rheumatol; 1995 May; 7(3):167-73. PubMed ID: 7612407
    [Abstract] [Full Text] [Related]

  • 4. Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis.
    Schiff MH, Whelton A.
    Semin Arthritis Rheum; 2000 Dec; 30(3):196-208. PubMed ID: 11124283
    [Abstract] [Full Text] [Related]

  • 5. Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis.
    Singh G, Fries JF, Williams CA, Zatarain E, Spitz P, Bloch DA.
    J Rheumatol; 1991 Feb; 18(2):188-94. PubMed ID: 1673721
    [Abstract] [Full Text] [Related]

  • 6. Disease-modifying antirheumatic drugs, including methotrexate, sulfasalazine, gold, antimalarials, and penicillamine.
    Girgis L, Conaghan PG, Brooks P.
    Curr Opin Rheumatol; 1994 May; 6(3):252-61. PubMed ID: 7914739
    [Abstract] [Full Text] [Related]

  • 7. DMARDs in the treatment of rheumatoid arthritis: current agents and future developments.
    Simon LS.
    Int J Clin Pract; 2000 May; 54(4):243-9. PubMed ID: 10912314
    [Abstract] [Full Text] [Related]

  • 8. Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.
    Rau R, Schleusser B, Herborn G, Karger T.
    J Rheumatol; 1998 Aug; 25(8):1485-92. PubMed ID: 9712088
    [Abstract] [Full Text] [Related]

  • 9. Disease-modifying antirheumatic drugs, including methotrexate, sulfasalazine, gold, antimalarials, and D-penicillamine.
    Conaghan PG, Brooks P.
    Curr Opin Rheumatol; 1993 May; 5(3):276-81. PubMed ID: 8099805
    [Abstract] [Full Text] [Related]

  • 10. Variations and trends in the prescription of initial second line therapy for patients with rheumatoid arthritis.
    Galindo-Rodriguez G, Avina-Zubieta JA, Fitzgerald A, LeClerq SA, Russell AS, Suarez-Almazor ME.
    J Rheumatol; 1997 Apr; 24(4):633-8. PubMed ID: 9101493
    [Abstract] [Full Text] [Related]

  • 11. Intention-to-treat analysis of 200 patients with rheumatoid arthritis 12 years after random allocation to either sulfasalazine or penicillamine.
    Capell HA, Maiden N, Madhok R, Hampson R, Thomson EA.
    J Rheumatol; 1998 Oct; 25(10):1880-6. PubMed ID: 9779839
    [Abstract] [Full Text] [Related]

  • 12. Disease-modifying antirheumatic drugs. Potential effects in older patients.
    Gardner G, Furst DE.
    Drugs Aging; 1995 Dec; 7(6):420-37. PubMed ID: 8601050
    [Abstract] [Full Text] [Related]

  • 13. [Combination therapy of rheumatoid arthritis].
    Hansen A, Jensen T.
    Ugeskr Laeger; 1998 Sep 28; 160(40):5772-6. PubMed ID: 9782754
    [Abstract] [Full Text] [Related]

  • 14. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
    Proudman SM, Keen HI, Stamp LK, Lee AT, Goldblatt F, Ayres OC, Rischmueller M, James MJ, Hill CL, Caughey GE, Cleland LG.
    Semin Arthritis Rheum; 2007 Oct 28; 37(2):99-111. PubMed ID: 17391739
    [Abstract] [Full Text] [Related]

  • 15. The role of anti-malarials in rheumatoid arthritis--the American experience.
    Khraishi MM, Singh G.
    Lupus; 1996 Jun 28; 5 Suppl 1():S41-4. PubMed ID: 8803910
    [Abstract] [Full Text] [Related]

  • 16. Disease-modifying antirheumatic drugs: gold, penicillamine, antimalarials, and sulfasalazine.
    McConkey B.
    Curr Opin Rheumatol; 1991 Jun 28; 3(3):348-54. PubMed ID: 1679342
    [Abstract] [Full Text] [Related]

  • 17. Etanercept in combination with sulfasalazine, hydroxychloroquine, or gold in the treatment of rheumatoid arthritis.
    O'Dell JR, Petersen K, Leff R, Palmer W, Schned E, Blakely K, Haire C, Fernandez A.
    J Rheumatol; 2006 Feb 28; 33(2):213-8. PubMed ID: 16358366
    [Abstract] [Full Text] [Related]

  • 18. Rheumatoid arthritis: a pharmacologic overview.
    Pinals RS.
    Am Fam Physician; 1988 Mar 28; 37(3):145-52. PubMed ID: 2894754
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate.
    O'Dell JR, Haire C, Erikson N, Drymalski W, Palmer W, Maloley P, Klassen LW, Wees S, Moore GF.
    J Rheumatol Suppl; 1996 Mar 28; 44():72-4. PubMed ID: 8833058
    [Abstract] [Full Text] [Related]

  • 20. Disappointing longterm results with disease modifying antirheumatic drugs. A practice based study.
    Galindo-Rodriguez G, Aviña-Zubieta JA, Russell AS, Suarez-Almazor ME.
    J Rheumatol; 1999 Nov 28; 26(11):2337-43. PubMed ID: 10555887
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.